The Cancer-Killing Antibody That Fooled $77M Out of Big Pharma's Pockets

If traditional antibodies are like snipers who can only shoot targets standing in windows, Crossbow's T-Bolt antibodies can see through the walls.

What the Money Is Actually For

Crossbow isn't sitting on a pile of preclinical slides and a dream. Their lead candidate, CBX-250, is already in a Phase 1 trial called CROSSCHECK-001. The drug targets a specific peptide-HLA combination found on myeloid cancer cells, making it relevant to patients with relapsed or refractory AML, CML, MDS, and CMML (all blood cancers that are notoriously hard to treat when they come back).

The first patient was dosed in the fall of 2025. Initial data from that trial is expected by the end of 2026. That's the big milestone this money needs to hit.

But there's a second act. Crossbow's pipeline includes CBX-663, which targets a peptide derived from telomerase (TERT), an enzyme that's overactive in a wide range of cancers, both blood and solid tumors. The company plans to file its IND and start a Phase 1 trial for CBX-663 in Q3 2026. If CBX-250 proves the platform works in one cancer, CBX-663 could blow the doors open across many.

The Funding Environment Makes This Even More Interesting

Let's zoom out. Biotech Series B rounds in 2025 and early 2026 have been a study in natural selection. Fewer companies are getting funded, but the ones that do are raising big. Mirador Therapeutics pulled in $250 million. ILiAD Biotechnologies grabbed $115 million. EpiBiologics closed $107 million.

Crossbow's $77 million fits squarely in this trend: investors are concentrating capital on companies with clinical-stage assets and differentiated platforms. The spray-and-pray era of biotech VC is over. Money is flowing toward companies that can show, not just tell.

What makes Crossbow's round stand out is the strategic angle. Taiho Ventures isn't just writing checks for returns. Taiho Pharmaceutical uses its venture arm to get early access to drug candidates and forge business alliances. Its past investments have directly fed Taiho's pipeline, most notably with Cullinan Pearl, which Taiho spun out in 2019 and then reacquired in 2022, bringing zipalertinib (now in Phase 3 for lung cancer) back in-house.

When Taiho co-leads your round, that's not passive investing. That's a relationship with a longer runway.

The People Behind the Arrows

Crossbow emerged from stealth in July 2023 with an $80 million Series A, which means the company has now raised $157 million total in under three years. It was co-founded by Patrick Baeuerle, Todd Foley, and Geraldine Paulus, and incubated at MPM BioImpact.

But the person running the show is CEO Briggs Morrison, M.D., who previously served as AstraZeneca's Chief Medical Officer. That kind of resume doesn't guarantee success, but it does signal that the company has leadership that's navigated large-scale drug development before.

Preclinical data on both CBX-250 and CBX-663 will be presented at the AACR Annual Meeting in San Diego this April. For investors and competitors watching Crossbow, that conference will be the first real public look at the science behind the hype.

The Bottom Line

Crossbow is making a bold claim: that the future of cancer immunotherapy lies in targeting what's inside the cell, not just what's sitting on its surface. If T-Bolt works as advertised, it could unlock a universe of cancer targets that current antibodies simply can't reach.

The $77 million buys them roughly a year to prove it. Phase 1 data from CBX-250 by year's end, a second candidate entering the clinic in Q3, and preclinical updates at AACR next month. That's a packed schedule for a company still in its early chapters.

But with Taiho, Pfizer, Lilly, and Arkin all at the table, the smart money clearly thinks Crossbow is aiming at the right target. Now they just have to hit it.